XenoTech Unveils CryostaX

XenoTech has introduced its new product in the field of cryopreserved pooled human hepatocytes, CryostaX.

The company said that CryostaX is the largest single-freeze pool of cryopreserved human hepatocytes. This patent-pending product offers large lots of hepatocytes that allow long-term predictable results. Like all of the XenoTech products, CryostaX undergoes a thorough data review to ensure a dependable, high-quality source of human hepatocytes, an integral part of any drug development program.

Andrew Parkinson, CEO and chief scientific officer of XenoTech, said: “CryostaX is an example of our continuous commitment to provide the best products to advance in vitro drug development research.”

“We’re committed to producing high quality scientific tools that provide great value for pharmaceutical researchers. In addition to quality and value offered, CryostaX allows for future customisation of pooled human hepatocytes for the in-depth pursuit of safe drug candidates.”

XenoTech is a contract research organization with expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes.